AnaptysBio (ANAB) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inhibrx Biosciences (INBX) has outperformed AnaptysBio (ANAB) over the past year, gaining 178.7% versus a gain of 129.2%. AnaptysBio is the larger company by market cap ($1.38 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | INBX |
|---|---|---|
| Share price | $46.21 | $92.76 |
| Market cap | $1.38B | $1.37B |
| 1-day change | +1.23% | -0.64% |
| YTD return | +41.24% | +18.18% |
| 1-year return | +129.24% | +178.69% |
| 5-year return | +138.84% | — |
| Forward P/E | 9.12 | — |
| EPS (TTM) | $-0.96 | $-8.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $155.29 |
| 52-week low | $20.18 | $28.16 |
| Distance from 52-week high | -36.14% | -40.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.81% | +187.48% |
| Average volume | 563.32K | 291.93K |
| Shares outstanding | 29.90M | 14.72M |
| Employees | — | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INBX has outperformed ANAB by 49.4 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
ANAB vs INBX FAQ
Which is bigger, AnaptysBio or Inhibrx Biosciences?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.38B compared with $1.37B for Inhibrx Biosciences (INBX).
Which stock has performed better over the past year, ANAB or INBX?
INBX returned +178.69% over the past 12 months, compared with +129.24% for ANAB (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Inhibrx Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AnaptysBio and Biotechnology: Biological Products (No Diagnostic Substances) for Inhibrx Biosciences.